$VCEL
Vericel Corp Stock $vcel

$vcel Overview Financials Valuation SEC Filings Company Website

2015 Q4 Form 10-Q Financial Statement

#000162828015008745 Filed on November 13, 2015

Income Statement

Concept	2015 Q4	2015 Q3	2014 Q4
Revenue	$15.42M	$11.31M	$14.71M
YoY Change	4.86%	17.09%	146960.0%
Cost Of Revenue	$7.230M	$6.772M	$6.650M
YoY Change	8.72%	22.42%
Gross Profit	$8.191M	$4.537M	$7.954M
YoY Change	2.98%	9.96%	79440.0%
Gross Profit Margin	53.12%	40.12%	54.09%
Selling, General & Admin	$5.740M	$5.674M	$4.010M
YoY Change	43.14%	31.56%	147.53%
% of Gross Profit	70.08%	125.06%	50.41%
Research & Development	$7.400M	$3.740M	$5.790M
YoY Change	27.81%	-52.27%	74.4%
% of Gross Profit	90.34%	82.43%	72.79%
Depreciation & Amortization	$410.0K	$400.0K	$250.0K
YoY Change	64.0%	100.0%	150.0%
% of Gross Profit	5.01%	8.82%	3.14%
Operating Expenses	$13.15M	$9.414M	$9.800M
YoY Change	34.18%	-22.51%	98.78%
Operating Profit	-$4.957M	-$4.877M	-$2.345M
YoY Change	111.39%	-39.2%	-52.34%
Interest Expense	$0.00	$2.000K	$140.0K
YoY Change	-100.0%	100.0%	-93.03%
% of Operating Profit
Other Income/Expense, Net	$50.00K	$461.0K	-$160.0K
YoY Change	-131.25%	-58.28%
Pretax Income	-$4.910M	-$4.420M	-$2.370M
YoY Change	107.17%	-36.13%	-18.84%
Income Tax
% Of Pretax Income
Net Earnings	-$4.910M	-$4.416M	-$2.370M
YoY Change	107.17%	-36.16%	-18.84%
Net Earnings / Revenue	-31.84%	-39.05%	-16.12%
Basic Earnings Per Share
Diluted Earnings Per Share	-$207.3K	-$185.8K	-$99.33K
COMMON SHARES
Basic Shares Outstanding	23.79M shares	23.79M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q4	2015 Q3	2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$14.60M	$18.70M	$30.30M
YoY Change	-51.82%	-50.27%	274.07%
Cash & Equivalents	$14.60M	$18.70M	$30.30M
Short-Term Investments
Other Short-Term Assets	$464.0K	$514.0K	$1.036M
YoY Change	-55.21%	-65.73%	153.3%
Inventory	$1.379M	$1.639M	$1.920M
Prepaid Expenses
Receivables	$10.92M	$7.639M	$8.191M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$27.34M	$28.52M	$41.49M
YoY Change	-34.1%	-36.21%	389.5%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.049M	$4.315M	$2.892M
YoY Change	40.01%	79.79%	291.34%
Goodwill
YoY Change
Intangibles	$2.917M	$2.987M	$3.197M
YoY Change	-8.76%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$6.966M	$7.302M	$6.089M
YoY Change	14.4%	28.11%	723.95%
TOTAL ASSETS
Total Short-Term Assets	$27.34M	$28.52M	$41.49M
Total Long-Term Assets	$6.966M	$7.302M	$6.089M
Total Assets	$34.31M	$35.82M	$47.58M
YoY Change	-27.89%	-28.93%	416.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.588M	$4.995M	$5.824M
YoY Change	30.29%	99.8%	147.3%
Accrued Expenses	$3.603M	$85.00K	$4.714M
YoY Change	-23.57%	-97.26%	1503.4%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$12.11M	$9.261M	$11.83M
YoY Change	2.36%	-25.91%	122.31%
LONG-TERM LIABILITIES
Long-Term Debt	$71.00K	$81.00K	$109.0K
YoY Change	-34.86%	-19.0%
Other Long-Term Liabilities		$66.00K	$0.00
YoY Change
Total Long-Term Liabilities	$0.00	$147.0K	$109.0K
YoY Change	-100.0%	47.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.11M	$9.261M	$11.83M
Total Long-Term Liabilities	$0.00	$147.0K	$109.0K
Total Liabilities	$12.18M	$9.408M	$11.94M
YoY Change	2.02%	-25.33%	124.36%
SHAREHOLDERS EQUITY
Retained Earnings	-$324.0M
YoY Change
Common Stock	$307.8M	$307.2M	$305.0M
YoY Change	0.9%		20.43%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$3.150M		$0.00
YoY Change
Treasury Stock Shares	1.250M shares		1.250M shares
Shareholders Equity	$22.13M	$26.41M	$35.64M
YoY Change
Total Liabilities & Shareholders Equity	$34.31M	$35.82M	$47.58M
YoY Change	-27.89%	-28.93%	416.32%

Cashflow Statement

Concept	2015 Q4	2015 Q3	2014 Q4
OPERATING ACTIVITIES
Net Income	-$4.910M	-$4.416M	-$2.370M
YoY Change	107.17%	-36.16%	-18.84%
Depreciation, Depletion And Amortization	$410.0K	$400.0K	$250.0K
YoY Change	64.0%	100.0%	150.0%
Cash From Operating Activities	-$4.040M	-$720.0K	-$6.240M
YoY Change	-35.26%	-91.46%	43.78%
INVESTING ACTIVITIES
Capital Expenditures	-$100.0K	-$770.0K	-$750.0K
YoY Change	-86.67%	1000.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$100.0K
YoY Change	-100.0%	-100.0%
Cash From Investing Activities	-$90.00K	-$780.0K	-$650.0K
YoY Change	-86.15%	-69.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	-10.00K	-300.0K
YoY Change	-100.0%	-100.02%	-118.99%
NET CHANGE
Cash From Operating Activities	-4.040M	-720.0K	-6.240M
Cash From Investing Activities	-90.00K	-780.0K	-650.0K
Cash From Financing Activities	0.000	-10.00K	-300.0K
Net Change In Cash	-4.130M	-1.510M	-7.190M
YoY Change	-42.56%	-104.98%	160.51%
FREE CASH FLOW
Cash From Operating Activities	-$4.040M	-$720.0K	-$6.240M
Capital Expenditures	-$100.0K	-$770.0K	-$750.0K
Free Cash Flow	-$3.940M	$50.00K	-$5.490M
YoY Change	-28.23%	-100.6%	26.5%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	0	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	3930000	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-552000	USD
	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	1004000	USD
	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	0	USD
CY2014Q3	astm	Amortizationof Intangible Assets Minimum Materiality Thresholdfor Amortization Expense AmortizationofIntangibleAssetsMinimumMaterialityThresholdforAmortizationExpense	100000	USD
	astm	Amortizationof Intangible Assets Minimum Materiality Thresholdfor Amortization Expense AmortizationofIntangibleAssetsMinimumMaterialityThresholdforAmortizationExpense	100000	USD
CY2015Q3	astm	Common Stock Remaining Capacity CommonStockRemainingCapacity	7800000	USD
CY2011Q3	astm	Common Stock Value Registeredon Form S3 CommonStockValueRegisteredonFormS3	100000000	USD
CY2012Q1	astm	Convertible Preferred Stock Conversion Period ConvertiblePreferredStockConversionPeriod	P5Y
	astm	Foreign Currency Translation Gain ForeignCurrencyTranslationGain	-154000	USD
	astm	Foreign Currency Translation Gain ForeignCurrencyTranslationGain	5000	USD
CY2015Q3	astm	Operating And Capital Leases Future Minimum Payments Due OperatingAndCapitalLeasesFutureMinimumPaymentsDue	7045000	USD
CY2015Q3	astm	Operating And Capital Leases Future Minimum Payments Due Current OperatingAndCapitalLeasesFutureMinimumPaymentsDueCurrent	1017000	USD
CY2015Q3	astm	Operating And Capital Leases Future Minimum Payments Due In Four Years OperatingAndCapitalLeasesFutureMinimumPaymentsDueInFourYears	379000	USD
CY2015Q3	astm	Operating And Capital Leases Future Minimum Payments Due In Three Years OperatingAndCapitalLeasesFutureMinimumPaymentsDueInThreeYears	1493000	USD
CY2015Q3	astm	Operating And Capital Leases Future Minimum Payments Due In Two Years OperatingAndCapitalLeasesFutureMinimumPaymentsDueInTwoYears	4156000	USD
CY2015Q3	astm	Operating And Capital Leases Future Minimum Payments Due Thereafter OperatingAndCapitalLeasesFutureMinimumPaymentsDueThereafter	0	USD
	astm	Purchase Obligation Automatic Renewal Term PurchaseObligationAutomaticRenewalTerm	P5Y
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Period End Date DocumentPeriodEndDate	2015-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000887359
CY2015Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	23789219	shares
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Entity Registrant Name EntityRegistrantName	Vericel Corp
CY2014Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4714000	USD
CY2015Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3311000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5824000	USD
CY2015Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	4995000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8191000	USD
CY2015Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7639000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	339000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	855000	USD
	astm	Purchase Obligation Renewal Option Term PurchaseObligationRenewalOptionTerm	P5Y
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-521000	USD
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	0	USD
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	43000	USD
CY2014Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	2044000	USD
CY2015Q3	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	1483000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	605000	USD
CY2015Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	85000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4397000	USD
CY2015Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5298000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-71000	USD
CY2015Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-71000	USD
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	USD
CY2015Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	54000	USD
CY2015Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	200000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2300000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4200000	shares
CY2014Q4	us-gaap	Asset Retirement Obligation Current AssetRetirementObligationCurrent	348000	USD
CY2015Q3	us-gaap	Asset Retirement Obligation Current AssetRetirementObligationCurrent	53000	USD
	us-gaap	Asset Retirement Obligation Liabilities Settled AssetRetirementObligationLiabilitiesSettled	0	USD
	us-gaap	Asset Retirement Obligation Liabilities Settled AssetRetirementObligationLiabilitiesSettled	-267000	USD
CY2014Q4	us-gaap	Assets Assets	47579000	USD
CY2015Q3	us-gaap	Assets Assets	35818000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	41490000	USD
CY2015Q3	us-gaap	Assets Current AssetsCurrent	28516000	USD
CY2014Q3	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount	0	USD
	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount	3634000	USD
CY2015Q3	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount	0	USD
	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount	0	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	65000	USD
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	153000	USD
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
CY2015Q3	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	129000	USD
CY2015Q3	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	32000	USD
CY2015Q3	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	43000	USD
CY2015Q3	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	43000	USD
CY2015Q3	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	0	USD
CY2015Q3	us-gaap	Capital Leases Future Minimum Payments Remainder Of Fiscal Year CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear	11000	USD
CY2013Q4	us-gaap	Cash Cash	8059000	USD
CY2014Q3	us-gaap	Cash Cash	37578000	USD
CY2014Q4	us-gaap	Cash Cash	30343000	USD
CY2015Q3	us-gaap	Cash Cash	18724000	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2015Q3	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2015Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23789000	shares
CY2015Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23789000	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23786000	shares
CY2015Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23786000	shares
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	305008000	USD
CY2015Q3	us-gaap	Common Stock Value CommonStockValue	307207000	USD
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6992000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17620000	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4416000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11430000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	3158000	USD
CY2014Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	5532000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	10541000	USD
CY2015Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	6772000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	19241000	USD
CY2014Q3	us-gaap	Depreciation Depreciation	200000	USD
	us-gaap	Depreciation Depreciation	400000	USD
CY2015Q3	us-gaap	Depreciation Depreciation	400000	USD
	us-gaap	Depreciation Depreciation	1000000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	496000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1182000	USD
CY2014Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	307685000	USD
CY2015Q3	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	319115000	USD
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.82
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.90
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.26
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.69
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-13000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	0	USD
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1281000	USD
CY2015Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1340000	USD
CY2014Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-949000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	155000	USD
CY2015Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-461000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-256000	USD
CY2014Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	20000	USD
CY2015Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	1797000	USD
CY2015Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	70000	USD
CY2015Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	280000	USD
CY2015Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	280000	USD
CY2015Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	280000	USD
CY2015Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	280000	USD
CY2015Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2987000	USD
CY2014Q3	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	154000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	154000	USD
CY2015Q3	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-5000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	5000	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	35000	USD
CY2014Q3	us-gaap	Gross Profit GrossProfit	4126000	USD
	us-gaap	Gross Profit GrossProfit	3549000	USD
CY2015Q3	us-gaap	Gross Profit GrossProfit	4537000	USD
	us-gaap	Gross Profit GrossProfit	16507000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-69000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-899000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1071000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1109000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-434000	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	11000	USD
CY2014Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3197000	USD
CY2015Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2987000	USD
CY2014Q3	us-gaap	Interest Expense InterestExpense	1000	USD
	us-gaap	Interest Expense InterestExpense	4000	USD
CY2015Q3	us-gaap	Interest Expense InterestExpense	2000	USD
	us-gaap	Interest Expense InterestExpense	6000	USD
CY2014Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	384000	USD
CY2015Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	164000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	1920000	USD
CY2015Q3	us-gaap	Inventory Net InventoryNet	1639000	USD
CY2014Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1078000	USD
CY2015Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	1273000	USD
CY2014Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	458000	USD
CY2015Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	202000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	55000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	621000	USD
CY2014Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	3000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	9000	USD
CY2015Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	7000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	29000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	11938000	USD
CY2015Q3	us-gaap	Liabilities Liabilities	9408000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	47579000	USD
CY2015Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35818000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11829000	USD
CY2015Q3	us-gaap	Liabilities Current LiabilitiesCurrent	9261000	USD
CY2014Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	109000	USD
CY2015Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	81000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	29519000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-11619000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	50230000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-15000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1532000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-2295000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-19166000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-9309000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-6917000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-17550000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-4416000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-11430000	USD
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8451000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-21976000	USD
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6137000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16395000	USD
CY2014Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1105000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3638000	USD
CY2015Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	461000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	284000	USD
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	12148000	USD
	us-gaap	Operating Expenses OperatingExpenses	24737000	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	9414000	USD
	us-gaap	Operating Expenses OperatingExpenses	28221000	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-8022000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-21188000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4877000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11714000	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	6916000	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	347000	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1450000	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	4113000	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	0	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	1006000	USD
CY2014Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1400000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	2200000	USD
CY2015Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1300000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	3800000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	436000	USD
CY2015Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	350000	USD
CY2014Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1036000	USD
CY2015Q3	us-gaap	Other Assets Current OtherAssetsCurrent	514000	USD
CY2014Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-75000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-70000	USD
CY2015Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2014Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	210000	USD
CY2015Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	130000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2015Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	66000	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-35000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	1450000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	82000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2330000	USD
CY2014Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1534000	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	4426000	USD
CY2015Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1721000	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	4965000	USD
CY2014Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	38389000	USD
CY2015Q3	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	38389000	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	50236000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7289000	USD
CY2015Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9613000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2892000	USD
CY2015Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4315000	USD
CY2015Q3	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	300000	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	6000	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	26000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	2500000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7835000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15470000	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3740000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11486000	USD
CY2014Q2	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Inception To Date RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate	80	position
CY2014Q2	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Inception To Date Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent	0.30
CY2015Q3	us-gaap	Restructuring Charges RestructuringCharges	100000	USD
	us-gaap	Restructuring Charges RestructuringCharges	3100000	USD
CY2015Q3	us-gaap	Restructuring Reserve RestructuringReserve	0	USD
CY2014Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	9658000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	14090000	USD
CY2015Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	11309000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	35748000	USD
CY2014Q3	us-gaap	Sales Revenue Net SalesRevenueNet	9658000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	14090000	USD
CY2015Q3	us-gaap	Sales Revenue Net SalesRevenueNet	11309000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	35748000	USD
CY2014Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4313000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9267000	USD
CY2015Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5674000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	16735000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	653000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2188000	USD
	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	965000	USD
	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	0	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	35641000	USD
CY2015Q3	us-gaap	Stockholders Equity StockholdersEquity	26410000	USD
CY2014Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1081000	USD
CY2015Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	825000	USD
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10273000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	7569000	shares
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23788000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23786000	shares
	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements included herein have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC).  The preparation of condensed consolidated financial statements in conformity with generally accepted accounting principles in the United States of America (U.S. GAAP) requires management to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations. The financial statements reflect, in the opinion of management, all adjustments (consisting only of normal, recurring adjustments) necessary to state fairly the financial position and results of operations as of and for the periods indicated.  The results of operations for the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, are not necessarily indicative of the results to be expected for the full year or for any other period.  The </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;"> condensed consolidated balance sheet data was derived from the Company’s audited consolidated financial statements, but does not include all disclosures required by U.S. GAAP.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;">, as filed with the SEC on March 25, 2015 (Annual Report).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements include the accounts of Vericel and its wholly-owned subsidiaries, Marrow Donation, LLC, located in San Diego, California, and Vericel Denmark ApS, in Kastrup, Demark (collectively, the Company).  All inter-company transactions and accounts have been eliminated in consolidation.  Aastrom Biosciences GmbH ceased operations in 2014.</font></div></div>
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vericel Corporation a Michigan corporation, which was formerly known as Aastrom Biosciences, Inc. (the Company, Vericel, we, us or our), was incorporated in March 1989 and began employee-based operations in 1991. On May 30, 2014, Vericel completed the acquisition of certain assets and assumed certain liabilities of Sanofi, a French société anonyme (Sanofi), including all of the outstanding equity interests of Genzyme Biosurgery ApS (Genzyme Denmark or the Danish subsidiary) (now known as Vericel Denmark ApS), a wholly-owned subsidiary of Sanofi, and over </font><font style="font-family:inherit;font-size:10pt;">250</font><font style="font-family:inherit;font-size:10pt;"> patents and patent applications of Sanofi and certain of its subsidiaries for purposes of acquiring the portion of the cell therapy and regenerative medicine business (the CTRM Business), which researches, develops, manufactures, markets and sells the Carticel</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;">, MACI™, and Epicel</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> products. The Company is a fully integrated, commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of innovative therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. Vericel has marketed products as well as developmental stage product candidates and the Company’s goal is to become the leader in cell therapy and regenerative medicine by developing, manufacturing and marketing best-in-class therapies for patients with significant unmet medical needs.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates its business primarily in the U.S. in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> reportable segment — the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Successful future operations are subject to several technical hurdles and risk factors, including satisfactory product development, timely initiation and completion of clinical trials, regulatory approval and market acceptance of the Company’s products.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-15-008745-index-headers.html	Edgar Link	pending
0001628280-15-008745-index.html	Edgar Link	pending
0001628280-15-008745.txt	Edgar Link	pending
0001628280-15-008745-xbrl.zip	Edgar Link	pending
acipicture.jpg	Edgar Link	pending
astm-20150930.xml	Edgar Link	completed
astm-20150930.xsd	Edgar Link	pending
astm-20150930_cal.xml	Edgar Link	unprocessable
astm-20150930_def.xml	Edgar Link	unprocessable
astm-20150930_lab.xml	Edgar Link	unprocessable
astm-20150930_pre.xml	Edgar Link	unprocessable
ex101aci-maixsupplyagreeme.htm	Edgar Link	pending
ex311q32015-ceosoxcertific.htm	Edgar Link	pending
ex312q32015-cfosoxcertific.htm	Edgar Link	pending
ex321q32015-ceosection906c.htm	Edgar Link	pending
ex322q32015-cfosection906c.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
matricel.jpg	Edgar Link	pending
matricela01.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vericel9301510q.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VCEL
Vericel Corp Stock $vcel

2015 Q4 Form 10-Q Financial Statement

#000162828015008745 Filed on November 13, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VCEL Vericel Corp Stock $vcel

2015 Q4 Form 10-Q Financial Statement

#000162828015008745 Filed on November 13, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VCEL
Vericel Corp Stock $vcel